Patients with SARD-ILD-PPF who continued nintedanib for 12 months or longer had better outcomes than those who discontinued therapy.

The good news? I took a sliver out of Simms’s head-to-head lead. The bad news? I was a not-great 9-7 for Week 17. Simms was 8-8. It puts him up by five games, with 29 games (including postseason) to ...

1. Seahawks (last week No. 1; 13-3): Another year, another Week 18 opportunity for Sam Darnold to win the No. 1 seed. 2. Patriots (No. 4; 13-3): They could have scored 100 against the Jets, if they ...

Following the clinical success of new agents like nerandomilast, the next critical steps for managing ILD involve dismantling financial and geographical barriers to access, and rigorously integrating ...

This video explains drop and torture tests and examines whether they are truly necessary for everyday users. By looking at durability, real-world risks, and potential downsides, it helps viewers ...

Following the recent approval of nerandomilast tablets for the treatment of idiopathic pulmonary fibrosis (IPF) in adults, the FDA has approved the medication for progressive pulmonary fibrosis as ...

“Patients with pulmonary edema generally describe breathlessness. Sometimes they feel like they are suffocating or breathing ...

AI-based imaging tools have shown potential in detecting treatment responses in IPF, supporting the use of ENV-101 and AI imaging as trial endpoints. The forced oscillation technique (FOT) may enhance ...

-- Progressive pulmonary fibrosis (PPF) is a life-threatening, progressive lung condition, causing a continuous decline in lung function.1,2 -- Affecting up to 100,000 people in the U.S. and up to 5.6 ...

The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults. Jascayd becomes the first and only preferential ...